GLUE — Monte Rosa Therapeutics, Inc. stock price, charts and financials

QT64Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.08
+0.70+4.55%
OverviewShort InterestFilings
GLUEQT64Monte Rosa Therapeutics, Inc.·NASDAQ
16.08+4.55%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OCUL+2.26%$8.59STOK+7.14%$31.67TSHA+7.27%$6.20AUPH+2.47%$14.93MESO+2.28%$14.80URGN+3.45%$39.92TYRA+1.53%$32.53IOVA+0.93%$4.36
Snapshot
Index-P/E-EPS (ttm)-1.86Insider Own-Shs Outstand84.48MPerf Week-31.83%
Market Cap1.30BForward P/E-EPS next Y-1.84Insider Trans-0.15%Shs Float59.76MPerf Month-36.47%
Enterprise Value668.29MPEG-EPS next Q-Inst Own-Short Float28.77%Perf Quarter-18.19%
Income-39.00MP/S10.48EPS this Y10.94%Inst Trans-Short Ratio14.82Perf Half Y-25.05%
Sales124.00MP/B2.49EPS next Y-10.86%ROA-17.65%Short Interest17.20MPerf YTD-1.91%
Book/sh6.18P/C1.95EPS next 5Y-ROE-40.99%52W High26.94 -40.32%Perf Year210.71%
Cash/sh7.88P/FCF-EPS past 3/5Y-ROIC-21.82%52W Low4.31 273.30%Perf 3Y127.51%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin95.28%Volatility8.26% 6.84%Perf 5Y-32.60%
Dividend TTM-EV/Sales5.39EPS Y/Y TTM-50.00%Oper. Margin-345.21%ATR (14)1.92Perf 10Y-
Dividend Ex-Date-Quick Ratio9.54Sales Y/Y TTM-Profit Margin-302.69%RSI (14)27.31Recom2.22
Dividend Gr. 3/5Y-Current Ratio9.54EPS Q/Q-178.95%SMA20-31.65%Beta1.48Target Price29.00
Payout0.00%Debt/Eq0.15Sales Q/Q-95.29%SMA50-25.76%Rel Volume1.75Prev Close15.38
Employees150LT Debt/Eq0.15EarningsAug 06SMA200-15.42%Avg Volume1.33MPrice16.08
IPO DateJun 24, 2021Option/ShortYes / YesEPS/Sales Surpr.-15.91% -61.65%Net Debt/EBITDA0.98Volume2,315,889Change4.55%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-03-26ReiteratedWedbushOutperform$37 → $27
Jul-31-26ReiteratedJefferiesBuy$40 → $25
Jul-27-26ReiteratedJefferiesBuy$31 → $40
Jun-30-26ReiteratedGuggenheimBuy$35
Jan-14-26ReiteratedPiper SandlerOverweight$37
Jan-07-26ReiteratedJefferiesBuy$22 → $31
Jan-07-26ReiteratedWedbushOutperform$26 → $37
Dec-17-25ReiteratedJefferiesBuy$22
Dec-16-25UpgradeWells FargoEqual Weight → Overweight$22
Dec-19-24DowngradeWells FargoOverweight → Equal Weight
Latest News
Company

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue1247600000
Cost of Goods Sold Incl. D&A8860010
Gross Profit11568-600-10
Selling, General and Administrative Excl. Other363532271641
Research and Development1421221058557237
Other Operating Expense-8-800000
Operating Income-54-81-143-112-73-28-8
Interest Expense0004000
Unusual Expense
———————
Non-Operating Income (Expense)141188-1-80
Net Income Before Taxes-40-70-135-109-74-36-8
Income Taxes-1300000
Consolidated Net Income-39-73-135-109-74-36-8
Net Income From Continuing Operations-39-73-135-109-74-36-8
Net Income-39-73-135-109-74-36-8
EPS (Recurring)-0.46-0.98-2.63-2.30-1.59-0.82-0.18
EPS (Basic, Before Extraordinaries)-0.46-0.98-2.63-2.30-1.59-0.82-0.18
EPS (Diluted)-0.46-0.98-2.63-2.30-1.59-0.82-0.18
EBITDA-31-62-129-101-72-27-8
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio10.506.76—————
Gross Margin92.7489.47—————
Operating Margin-43.55-106.58—————
Net Margin-31.45-96.05—————
Shares Outstanding83745147474444
Market Capitalization1,301514288358960——
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.51$21.58$14.64$7.70$0.77● Close Price0.00M0.42M0.85M1.27M1.69MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Warmuth MarkusPresident & CEOJul 16 '26Sale23.189,500220,219585,038Jul 17
Champoux JenniferChief Operating OfficerJul 15 '26Option Exercise3.984,35117,31766,722Jul 16
Champoux JenniferChief Operating OfficerJul 15 '26Sale23.384,351101,73062,371Jul 16
Townson SharonChief Scientific OfficerJul 06 '26Sale23.316,000139,84967,845Jul 07
Townson SharonChief Scientific OfficerJul 06 '26Option Exercise6.146,00036,84073,845Jul 07
Janku FilipChief Medical OfficerJun 30 '26Sale24.505,407132,47260,612Jul 01
Janku FilipChief Medical OfficerJun 30 '26Option Exercise13.415,40772,50866,019Jul 01
Manning Anthony M.DirectorJun 29 '26Option Exercise4.1610,00041,60010,000Jun 30
Janku FilipChief Medical OfficerJun 29 '26Option Exercise7.566,00045,36065,992Jun 30
Janku FilipChief Medical OfficerJun 29 '26Sale22.956,000137,70059,992Jun 30
Manning Anthony M.DirectorJun 29 '26Sale23.1110,000231,1000Jun 30
Janku FilipChief Medical OfficerJun 24 '26Option Exercise7.5630,000226,80089,992Jun 25
Janku FilipChief Medical OfficerJun 24 '26Sale21.4230,000642,68159,992Jun 25
Janku FilipChief Medical OfficerJun 23 '26Sale20.2211,845239,52259,992Jun 25
Champoux JenniferChief Operating OfficerJun 23 '26Option Exercise3.982,1758,65764,546Jun 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.